We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    ATIR101

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY)

This study is currently recruiting participants.
Verified November 2017 by Kiadis Pharma
Sponsor:
ClinicalTrials.gov Identifier:
NCT02999854
First Posted: December 21, 2016
Last Update Posted: November 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Kiadis Pharma
  Purpose
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic malignancy. An additional objective of the study is to compare the effect of the two treatments on quality of life.

Condition Intervention Phase
Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome Biological: ATIR101 Drug: Cyclophosphamide Procedure: T-cell depleted HSCT from a related, haploidentical donor Procedure: T-cell replete HSCT from a related, haploidentical donor Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy

Resource links provided by NLM:


Further study details as provided by Kiadis Pharma:

Primary Outcome Measures:
  • Graft-versus-host disease-free, relapse-free survival (GRFS) [ Time Frame: Until 2 years after the HSCT ]
    Time from randomization until grade III/IV acute GVHD, chronic GVHD requiring systemic immunosuppressive treatment, disease relapse, or death, whichever occurs first


Secondary Outcome Measures:
  • Overall survival (OS) [ Time Frame: Until 2 years after the HSCT ]
    Time from randomization until death from any cause

  • Progression-free survival (PFS) [ Time Frame: Until 2 years after the HSCT ]
    Time from randomization until relapse, disease progression, or death, whichever occurs first

  • Relapse-related mortality (RRM) [ Time Frame: Until 2 years after the HSCT ]
    Time from randomization to death due to disease relapse or disease progression

  • Transplant-related mortality (TRM) [ Time Frame: Until 2 years after the HSCT ]
    Time from randomization to death due to causes other than disease relapse or disease progression


Other Outcome Measures:
  • Immune reconstitution [ Time Frame: Until 2 years after the HSCT ]
    Time to CD3+ > 0.2×10E9/l in peripheral blood (at two consecutive measurements; time to first measurement)

  • Cumulative incidence of grade II-IV and grade III-IV acute graft-versus-host-disease (GVHD) [ Time Frame: Until 2 years after the HSCT ]
  • Cumulative incidence of moderate/severe chronic GVHD [ Time Frame: Until 2 years after the HSCT ]
  • Cumulative incidence of chronic GVHD requiring systemic immunosuppressive treatment [ Time Frame: Until 2 years after the HSCT ]
  • Duration of GVHD episodes [ Time Frame: Until 2 years after the HSCT ]
  • Cumulative incidence of NCI CTCAE grade 2-5 and grade 3-5 infections [ Time Frame: Until 2 years after the HSCT ]
    Viral, fungal, and bacterial infections

  • Cumulative incidence of NCI CTCAE grade 3-5 adverse events [ Time Frame: Until 2 years after the HSCT ]
    Viral, fungal, and bacterial infections

  • FACT-BMT total score (change from screening) [ Time Frame: Until 2 years after the HSCT ]
    Quality of life: Foundation for the Accreditation of Cellular Therapy - Bone Marrow Transplantation questionnaire (FACT-BMT)

  • SF-36 total score (change from screening) [ Time Frame: Until 2 years after the HSCT ]
    Quality of life: Short Form 36-item health survey (SF-36)

  • MDASI total score (change from screening) [ Time Frame: Until 2 years after the HSCT ]
    Quality of life: MD Anderson Symptom Inventory (MDASI)


Estimated Enrollment: 195
Anticipated Study Start Date: December 2017
Estimated Study Completion Date: May 2020
Estimated Primary Completion Date: May 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ATIR101
T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
Biological: ATIR101
ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
Procedure: T-cell depleted HSCT from a related, haploidentical donor
T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a myeloablative conditioning regimen
Active Comparator: PTCy
T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
Drug: Cyclophosphamide
High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
Procedure: T-cell replete HSCT from a related, haploidentical donor
T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a myeloablative conditioning regimen

Detailed Description:

Study CR-AIR-009 is a Phase III randomized controlled multicenter open-label study comparing two parallel groups. After signing informed consent, a total of 195 patients will be randomized in a 1:1 fashion to receive either a T-cell depleted hematopoietic stem cell transplantation (HSCT; CD34 selection) from a related, haploidentical donor, followed by ATIR101 infusion, or a T-cell replete HSCT, followed by a high dose of post-transplant cyclophosphamide (PTCy).

Randomization will use minimization to balance treatment groups with respect to underlying disease (AML, ALL, or MDS), Disease Risk Index (DRI; intermediate risk, high risk, or very high risk) and center. A stochastic treatment allocation procedure will be used so that the treatment assignment is random for all patients entered in the study.

Patients randomized in the ATIR101 group will receive a single ATIR101 dose of 2×10E6 viable T-cells/kg between 28 and 32 days after the HSCT. Patients randomized in the PTCy group will receive cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT. All patients will be followed up for 24 months post HSCT.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Any of the following hematologic malignancies:

    • Acute myeloid leukemia (AML) in first cytomorphological remission (< 5% blasts in the bone marrow) with Disease Risk Index (DRI) intermediate or above, or in second or higher cytomorphological remission
    • Acute lymphoblastic leukemia (ALL) in first or higher remission (< 5% blasts in the bone marrow)
    • Myelodysplastic syndrome (MDS): transfusion-dependent (requiring at least one transfusion per month), or intermediate or higher Revised International Prognostic Scoring System (IPSS-R) risk group
  • Clinical justification of allogeneic stem cell transplantation where a suitable HLA matched sibling or unrelated donor is unavailable in a timely manner. An unrelated donor search is not required for a patient to be eligible if the clinical situation dictates an urgent transplantation. Clinical urgency is defined as 6-8 weeks from referral to transplant center or low likelihood of finding a matched unrelated donor
  • Availability of a related haploidentical donor with ≥ 4/8 but < 7/8, or ≥ 5/10 but < 9/10 matches at the HLA-A, -B, -C, -DRB1, and/or -DQB1 loci, as determined by high resolution human leukocyte antigen (HLA)-typing
  • Karnofsky Performance Status (KPS) ≥ 70%
  • Male or female, age ≥ 18 years and ≤ 70 years. Patients aged ≥ 65 years must have a Sorror score ≤ 3
  • Availability of a donor aged ≥ 16 years and ≤ 75 years who is eligible according to local requirements and regulations
  • For females of childbearing potential who are sexually active and males who have sexual contact with a female of childbearing potential: willingness to use of reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) during study participation
  • Given written informed consent (patient and donor)

Exclusion Criteria:

  • Availability of a suitable HLA-matched sibling or unrelated donor in a donor search
  • Prior allogeneic hematopoietic stem cell transplantation
  • Diffusing capacity for carbon monoxide (hemoglobin corrected DLCO) < 50% predicted
  • Left ventricular ejection fraction < 45% (evaluated by echocardiogram or MUGA scan)
  • Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (CTCAE grade 2)
  • Bilirubin > 1.5 × upper limit of normal (CTCAE grade 2)
  • Creatinine clearance < 50 ml/min (calculated or measured)
  • Positive pregnancy test or breastfeeding of patient or donor (women of childbearing age only)
  • Estimated probability of surviving less than 3 months
  • Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
  • Known hypersensitivity to cyclophosphamide or any of its metabolites
  • Any contraindication for GVHD prophylaxis with mycophenolate mofetil, cyclosporine A, or tacrolimus
  • Known presence of HLA antibodies against the non-shared donor haplotype
  • Positive human immunodeficiency virus (HIV) test
  • Positive viral test of the donor for HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV) 1 (if tested), HTLV-2 (if tested), West Nile virus (WNV; if tested), or Zika virus (if tested)
  • Any other condition that, in the opinion of the investigator, makes the patient or donor ineligible for the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02999854


Contacts
Contact: Andrew Sandler, MD PhD +31 20 3140 250 clinicaltrials@kiadis.com

Locations
Belgium
Universitair Ziekenhuis Antwerpen Not yet recruiting
Antwerpen, Belgium, 2650
Principal Investigator: Wilfried Schroyens, MD         
Algemeen Ziekenhuis Sint-Jan Not yet recruiting
Brugge, Belgium, 8000
Principal Investigator: Dominik Selleslag, MD         
Institut Jules Bordet Not yet recruiting
Brussels, Belgium, 1000
Principal Investigator: Philippe Lewalle, MD         
Universitair Ziekenhuis Gasthuisberg Not yet recruiting
Leuven, Belgium, 3000
Principal Investigator: Johan Maertens, MD         
Centre Hospitalier Universitaire de Liège Not yet recruiting
Liège, Belgium, 4000
Principal Investigator: Yves Beguin, Prof MD         
Canada, Quebec
Maisonneuve-Rosemont Hospital Recruiting
Montreal, Quebec, Canada, H1T 2M4
Principal Investigator: Denis Claude Roy, Prof MD         
Germany
University Hospital Frankfurt, Goethe University Not yet recruiting
Frankfurt, Germany
Principal Investigator: Gesine Bug, MD         
University Medical Center Mainz Not yet recruiting
Mainz, Germany, 55131
Principal Investigator: Eva Maria Wagner, MD         
Universitätsklinikum Würzburg Not yet recruiting
Würzburg, Germany, 97080
Principal Investigator: Götz-Ulrich Grigoleit, MD         
Spain
University Hospital Barcelona Vall d' Hebron Not yet recruiting
Barcelona, Spain, 08035
Principal Investigator: David Valcarcel         
Hospital Puerta de Hierro Majadahonda Not yet recruiting
Madrid, Spain, 28220
Principal Investigator: Rafael Duarte, MD         
Servicio de Hematología Hospital, Universitari I politècnic La Fe Not yet recruiting
Valencia, Spain, 46026
Principal Investigator: Jose Luis Piñana, MD         
Sponsors and Collaborators
Kiadis Pharma
Investigators
Principal Investigator: Denis Claude Roy, Prof MD Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital (Stockholm, Sweden)
Principal Investigator: Stephan Mielke, Prof MD Julius Maximilian University of Würzburg (Würzburg, Germany)
  More Information

Responsible Party: Kiadis Pharma
ClinicalTrials.gov Identifier: NCT02999854     History of Changes
Other Study ID Numbers: CR-AIR-009
2016-004672-21 ( EudraCT Number )
First Submitted: December 19, 2016
First Posted: December 21, 2016
Last Update Posted: November 20, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Kiadis Pharma:
Haploidentical stem cell transplantation
Graft-versus-host disease
Immune reconstitution
Alloreactive T-cells
Photodynamic treatment
Hematologic malignancy
Transplant-related mortality
Overall survival
GRFS
GVHD

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists